ClinicalTrials.gg
RecruitingNCT07407894VITALUpdated Apr 22, 2026

iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

An interventional study of Bifidobacterium adolescentis iVS-1 and Placebo in Healthy Aging and Anti Aging, sponsored by Synbiotic Health. Recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Synbiotic Health · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.

Read the detailed description

Aging is associated with progressive physiological changes involving inflammation, cellular senescence, mitochondrial function, and alterations in the gut microbiome. Interventions targeting these biological processes may influence age-related health outcomes. The gut microbiome plays a central and modifiable role, influencing metabolic health, inflammation, neurocognitive outcomes, and systemic aging processes.

Reductions in Bifidobacterium adolescentis have been observed with aging and have been associated with metabolic and inflammatory changes. Preliminary studies suggest that supplementation with this species may affect biological pathways relevant to aging.

This study is a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation in adults aged 40-75 years. Participants will be randomized to receive iVS-1 (≥8 billion CFU per capsule) or placebo once daily for 150 days. Blood- and stool-based assessments and questionnaires about cognition, sleep quality, and quality of life will be collected at baseline, mid-intervention, and end of study.

Changes in these measures will be used to assess the relationship between Bifidobacterium adolescentis iVS-1 supplementation and biological aging markers, metabolic health, and functional health outcomes.

02

Conditions studied

  • Healthy Aging
  • Anti Aging

Keywords

  • Bifidobacterium adolescentis
  • iVS-1
  • Aging
  • Geroscience
  • Gut Microbiome
  • Probiotic
  • Healthspan
03

In context

Lead sponsor

Synbiotic Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 40-75 years.
  • : 20-34.9 kg/m².
  • Able and willing to sign and participate for the study duration.

Exclusion criteria

Exclusion Criteria:

  • Chronic disease history (liver, kidney, heart).
  • Current pregnancy and/or lactating.
  • Colonoscopy and/or its preparation within 4 weeks of screening.
  • Those who intend to have children during study period.
  • Current probiotic, prebiotics and/or metabolic-altering supplement use.
  • Those who are unable to cooperate with investigators and testing.
  • Known history of cancer and/or ongoing cancer treatments.
  • Abuse of drugs, alcohol, tobacco, nicotine and other substances.
  • History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.
  • History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.
  • Type 1 or 2 diabetes mellitus.
  • Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.
  • Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.
  • Significant weight loss (>20%) in prior one month.
  • Conditions affecting safety or outcome integrity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Bifidobacterium adolescentis iVS-1

    Probiotic Capsule

    Dietary Supplement: Bifidobacterium adolescentis iVS-1

  • Placebo comparator
    Placebo

    Placebo capsule

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBifidobacterium adolescentis iVS-1

    B. adolescentis iVS-1 (probiotic capsule) delivered orally once daily at a minimum of 8 billion CFU/day

  • Dietary supplementPlacebo

    Placebo capsule delivered orally once daily

06

What researchers measure

Primary outcomes

  1. Change in Biological Aging Biomarkers

    Changes in gene expression of biomarkers associated with biological aging, assessed by quantitative polymerase chain reaction (qPCR), compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

Secondary outcomes

  1. Change in Phenotypic Age

    Changes in Phenotypic Age calculated as a single value from blood-based biomarkers (albumin, creatinine, glucose, C-reactive protein, lymphocyte count, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count) and chronological age compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  2. Change in Bifidobacterium adolescentis iVS-1 Abundance

    Changes in fecal Bifidobacterium adolescentis iVS-1 abundance, assessed by quantitative polymerase chain reaction (qPCR), compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  3. Change in Metabolic Health

    Changes in metabolic health biomarkers assessed by Comprehensive Metabolic Panel (CMP) compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  4. Change in Lipid Profiles

    Changes in lipid profiles assed by a lipid panel compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  5. Change in Cognitive Function

    Changes in global and executive cognitive function assessed using validated cognitive assessments compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  6. Change in Sleep Quality

    Changes in sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI) compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  7. Change in Quality of Life

    Changes in quality-of-life scores assessed using the Short Form-36 Health Survey (SF-36) compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

Other outcomes

  1. Change in Gut Microbiota Composition

    Changes in gut microbiome composition and diversity assessed using metagenomic sequencing of fecal samples compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  2. Change in Gut Microbiota Function

    Changes in gut microbiome function assessed using metagenomic sequencing of fecal samples compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  3. Change in Fecal Metabolites

    Changes in fecal and plasma metabolites, including short-chain fatty acids (SCFAs), bile acids, and trimethylamine N-oxide (TMAO) compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  4. Change in Gut Permeability Markers

    Changes in gut permeability markers assessed using validated enzyme-linked immunosorbent assay (ELISA) techniques compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

  5. Change in Inflammatory Markers

    Changes in inflammatory markers assessed using validated enzyme-linked immunosorbent assay (ELISA) techniques compared across timepoints and between placebo and study product groups, including stratified analyses based on Bifidobacterium abundance.

    Time frame: Baseline to Day 150

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 12, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07407894
Lead sponsor
Synbiotic Health
Collaborators
MusB Research
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 1, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Shalini Jain, PhD
Contact
jains@musbresearch.com
813-419-0781
Indushekar Manjunatha
Contact
imanjunatha@musbresearch.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion